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ABSTRACT
Introduction
Endothelial dysfunction is one important mediator behind atherosclerosis. Maintained bioavailability of 
nitric oxide (NO) is critical to keep the fragile balance of endothelial function. Reduced NO arise from 
reduced production or increased elimination of NO. Arginase is an enzyme which metabolizes the substrate, 
L-arginine, which is used to produce NO. By competitive inhibition arginase may result in reduced NO-
bioavailability. Several risk factors for atherosclerosis such as diabetes mellitus and hypercholesterolemia 
are known to upregulate arginase expression and activity. Furthermore, experimental research has 
demonstrated beneficial effects of arginase inhibition. However, the functional significance of arginase in 
regulation of endothelial dysfunction in patients with cardiovascular disease is unknown. 
Aim
To evaluate the significance of arginase inhibition on endothelial function in patients with glucose and 
lipid abnormalities. 
Study I 
Forearm blood flow was determined during the administration of serotonin and sodium-nitroprusside 
to evaluate endothelium-dependent (EDV) and endothelium-independent (EIDV) vasodilatation, 
respectively, before and after 120 minutes intra-arterial (i.a.) administration of the arginase inhibitor Nω-
hydroxy-L-arginine (nor-NOHA) in patients with coronary artery disease (CAD) with and without type 
2 diabetes mellitus and in control subjects. Administration of nor-NOHA increased EDV in patients with 
CAD and diabetes and in patients with CAD alone via a NOS-dependent mechanism. Nor-NOHA did 
not affect EDV in control subjects. EIDV increased slightly in the CAD and diabetes group following 
nor-NOHA. 
Study II
Microvascular endothelial function was evaluated using laser Doppler flowmetry before and after 120 
minutes i.a administration of nor-NOHA. EDV was reduced in subjects with type 2 diabetes mellitus 
and microvascular dysfunction compared to healthy subjects. Administration of nor-NOHA reversed the 
impairment of microvascular endothelial function in the diabetes group, but not in the control group. The 
levels of amino acids reflecting arginase relative activity compared to NO synthase were significantly 
higher in subjects with diabetes mellitus, suggesting a higher arginase activity in this group.   
Study III
Flow-mediated vasodilatation (FMD) of the brachial artery was evaluated in patients with CAD without 
and with type 2 diabetes mellitus before and after 20 minutes of forearm ischemia and 20 minutes of 
reperfusion in a cross-over protocol randomized to either nor-NOHA or NaCl. FMD was reduced in 
CAD patients following ischemia-reperfusion (IR) and administration of NaCl. Administration of nor-
NOHA prevented the decrease in FMD after IR. In the group with CAD and diabetes, FMD following 
IR was significantly greater during administration of nor-NOHA than during administration of NaCl. 
Study IV
EDV and EIDV was determined in patients with familial hypercholesterolemia during relative low 
and high cholesterol levels compared to healthy control subjects before and after arginase inhibition. 
Baseline EDV did not differ between the groups. All groups increased their EDV in response to nor-
NOHA. The improvement in EDV was greater among patients with familial hypercholesterolemia 
subjects regardless of their cholesterol level or statins use. EIDV was not affected by nor-NOHA.  
Conclusions
Collectively, these results demonstrate the importance of arginase for the regulation of endothelial func-
tion in patients with CAD, type 2 diabetes mellitus, and hypercholesterolemia. Arginase is a promising 
therapeutic target in the future treatment of endothelial dysfunction in patients with CAD, type 2 diabe-
tes mellitus, or hypercholesterolemia.    
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SAMMANFATTNING
Bakgrund 
Åderförkalkning är idag den vanligaste orsaken till död i världen. Endotel dysfunktion är ett första-
dium till åderförkalkning och börjar tidigt i sjukdomsutvecklingen. Kväveoxid (NO) är en viktig mole-
kyl som produceras av endotelet och påverkar graden av inflammation, proppbildning och kärltonus. 
Många riskfaktorer för åderförkalkning har visat sig minska biotillgängligheten av NO. Arginas är ett 
enzym i endotelcellerna som metaboliserar arginin, dvs samma substrat som används för att bilda NO. 
Många experimentella studier har visat att ökad arginasaktivitet kan bidra till endoteldysfunktion vid 
ateroskleros, diabetes och hyperlipidemi. 
Målsättning
Att undersöka betydelsen av arginas vid endoteldysfunktion hos patienter med kranskärlssjukdom samt 
glukos- och lipidrubbningar. 
Studie I
Endotelfunktion i underarmen bestämdes före och efter 120 min i.a. administration av arginashämmaren 
Nω-hydroxy-L-arginin (nor-NOHA) hos patienter med CAD med och utan typ 2 diabetes samt friska 
kontroller. Administrering av nor-NOHA förbättrade endotelfunktionen hos patienter med CAD både 
med och utan diabetes men inte hos friska kontroller. Patienterna med diabetes hade signifikant bättre 
svar efter nor-NOHA jämfört med CAD patienter utan diabetes. Förbättringen i endotelfunktionen var 
beroende av det NO-producerande enzymet NO-syntas.  
Studie II 
Mikrovaskulär endotelfunktion undersöktes hos patienter med typ 2 diabetes och mikrovaskulär 
dysfunktion före och efter 120 min i.a. administrering av nor-NOHA. Diabetesgruppen hade en 
sänkt endotelfunktion jämfört med friska kontroller. Efter administration av nor-NOHA förbättrades 
endotelfunktionen i diabetesgruppen till samma nivå som hos friska kontroller.  Endotelfunktionen hos 
friska kontroller påverkades inte av interventionen. Aminosyror som speglar aktiviteten av arginas i 
jämförelse med NO-syntas var förhöjda i diabetesgruppen. 
Studie III
Flödesmedierad vasodilatation (FMD) av radialisartären bestämdes före och ischemi-reperfusion (IR) i 
underarmen hos patienter med kranskärlssjukdom med och utan typ 2 diabetes i ett cross-over protokoll 
där patienterna randomiserades i.a. infusion av till nor-NOHA eller NaCl. FMD minskade efter IR 
hos patienter med kranskärlssjukdom utan diabetesvid administrering av NaCl. Denna försämring 
motverkades av administrering av nor-NOHA. Även hos patienter med diabetes var FMD förbättrad 
vid administrering av nor-NOHA jämfört med NaCl efter IR. 
Studie IV
Endotelfunktion bestämdes hos patienter med familjär hyperkolesterolemi vid höga och låga 
kolesterolnivåer samt hos friska kontroller före och efter arginasblockad. Basal endotelfunktion skilde 
sig inte åt mellan grupperna. Alla grupperna förbättrades i endotelfunktion efter administration av nor-
NOHA. Förbättringen var signifikant större hos patienterna med familjär hyperkolesterolemi oavsett 
om dom hade lipidsänkande behandling eller ej. Endoteloberoende vasodilatation påverkades ej av 
arginasblockad.
Konklusion
Vi har visat att hämning av arginas spelar en betydelsefull roll för reglering av endotelfunktionen hos 
patienter med kranskärlssjukdom, diabetes och FH. Resultaten i denna avhandling talar för att hämning 
av arginas är en lovande terapi mot endoteldysfunktion hos patienter med utvecklad kranskärlssjukdom 
samt vid glukos- och lipidrubbningar. 
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BH4 Tetrahydrobiopterin 
CAD Coronary artery disease
EDV Endothelium-dependent vasodilatation
EIDV Endothelium-independent vasodilatation
FBF Forearm blood flow
FH Familial hypercholesterolemia 
FMD Flow-mediated vasodilatation
HDL High-density lipoprotein
i.a. Intra-arterial 
IR Ischemia-reperfusion
LDF Laser Doppler flowmetry
LDL Low-density lipoprotein 
L-NMMA L-NG-monomethyl arginine
LOX-1 Lectin-like oxidized low-density lipoprotein receptor 1
NO Nitric oxide 
Nor-NOHA Nω-hydroxy-nor-L-arginine
NOS Nitric oxide synthase
eNOS Endothelial nitric oxide synthase
iNOS Inducible nitric oxide synthase
nNOS Neuronal nitric oxide synthase
O2
- Superoxide 
ONOO- Peroxynitrite 
OxLDL Oxidized low-density lipoprotein
p38MAPK p38 mitogen-activated protein kinase
PGI2 Prostacyclin 
RBC Red blood cell
ROCK Rho-associated protein kinase
ROS Reactive oxygen species 
SNP Sodium nitroprusside
UKPDS UK Prospective Diabetes Study
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Cardiovascular disease and atherosclerosis
Cardiovascular disease is the most common cause of death in the world today. Approximately 
80% of deaths due to cardiovascular causes are due to diseases related to atherosclerosis such 
as myocardial infarction or stroke (1). Atherosclerosis is a chronic and systemic condition of 
inflammation and lipid accumulation in the arterial wall (2). The disease is slowly progres-
sive and is built up over decades as illustrated in Figure 1. Eventually, atherosclerosis results 
in formation of a plaque which may obstruct the blood flow and thereby cause ischemia to its 
distal tissue. The plaque may become unstable over time and rupture which triggers forma-
tion of a thrombus that may cause total occlusion of blood flow resulting in ischemia and cell 
death to either the heart (myocardial infarction) or brain (stroke) depending on the vascular 
territory of the plaque (3).
The incidence of cardiovascular disease is increasing worldwide especially in low-and 
middle-income countries. The WHO estimates that 75% of cardiovascular deaths occur in 
these countries (1). Worldwide approximately 14 million deaths are due to the complications 
of atherosclerosis such as coronary artery disease (CAD) and stroke (1). It is important to 
note that 46% of people dying from cardiovascular disease are below 70 years of age, which 
is a highly productive time in people’s lives (4). 
  
INTERHEART, a case-control study which compared patients with acute myocardial 
infarction with control subjects, found that nine risk factors are responsible for 90% of 
the events (5). These include smoking, elevated blood lipids (hyperlipidemia), systemic 
hypertension (hypertension), diabetes mellitus, lack of regular physical activity, adverse 
psychosocial conditions, and abdominal obesity. Analyses of changes in risk factors and 
medical interventions in populations over time have generated interesting data. The increased 
mortality from CAD in the population of Beijing between 1984 and 1999 was explained 
mainly by an increase in mean cholesterol and an increased prevalence of diabetes mellitus 
(6). During the same time period, the age-adjusted mortality from CAD decreased in the US, 
a change explained partly by a reduction of risk factors, i.e reductions in cholesterol, blood 
pressure, smoking prevalence, and physical inactivity. In contrast, the risk factors obesity and 
diabetes mellitus increased in prevalence (7). 
Diabetes mellitus and hyperlipidemia are considered to be two very important risk factors 
for the development of cardiovascular disease (8). The exact mechanisms involved in the 
pathogenesis of atherosclerosis and the development of CAD are still under investigation. 
Evidence suggests that endothelial dysfunction is closely linked to these risk factors, occurs 
early in the process of atherosclerosis and may amplify the progression and prognosis of the 
disease (Figure 1) (9, 10). 
Diabetes mellitus
Diabetes mellitus is a chronic condition characterized by an elevated glucose concentration in 
the blood. The WHO has defined diabetes mellitus as a fasting plasma glucose ≥ 7.0 mmol/l or 
plasma glucose ≥ 11.1 mmol/l two hours after an oral glucose load (75g). There are different 
INTRODUCTION AND BACKGROUND
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subgroups of diabetes mellitus, mainly type 1, type 2, gestational, and other specific types. 
Prediabetes is considered a condition of elevated plasma glucose, although not high enough 
to be classified as type 2 diabetes mellitus. Prediabetes individuals have an increased risk of 
developing type 2 diabetes and cardiovascular disease (11). According to the WHO definitions, 
impaired fasting glucose is the occurrence of plasma glucose between 6.1-6.9 mmol/l under 
fasting conditions while the individual still retains a normal response to oral glucose tolerance 
test (<7.8 mmol/l). Impaired glucose tolerance is defined as fasting glucose value <7.0 mmol/l 
in addition to plasma glucose value between 7.8-11.0 mmol/l after oral glucose tolerance test. 
The progression from impaired glucose tolerance to type 2 diabetes mellitus has been shown to 
be 90% over 20 years in the absence of therapeutic intervention (12).
Today there is an epidemic of diabetes. The International Diabetes Federation estimates that 
there were approximately 415 million patients suffering from diabetes in 2015 (8.8% of the 
world population). Of those, approximately 90% consist of type 2 diabetes. The estimated cost 
is about 673 billon US dollars per year (12% of global health expenditure) (11). In addition, 
the prevalence of diabetes mellitus is increasing. Estimations project that by 2040 the world-
wide prevalence will be 642 million people (10.4% of the world population) and will account 
for a major increase in the disease burden for health care systems and the economic cost to 
society. The epidemiology of the condition is also changing. Whereas the highest incidence 
and prevalence used to be seen in high-income countries, now about 75% of the patients 
exist in low- and middle-income countries (11). In Sweden (a high-income country), the 
prevalence of diabetes mellitus has increased by 61%, to approximately 352 400 patients 
(4.4% of the national population), between the years 2006-2013, which is probably because 
of longer average life expectancy since the incidence has been stable (13). 
Figure 1. The atherosclerosis process. Timeline over the progression of atherosclerosis. Endothelial 
dysfunction is an early mediator of atherosclerosis and is maintained throughout the disease. With permission 
from Professor Joep Perk who adapted it from Stary HC et al. Circulation. 1995;92:1355-1374 (3).
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The pathological process of type 2 diabetes mellitus often starts with decreased insulin 
sensitivity which in combination with inability of the pancreas to produce enough insulin 
yields a reduced glucose uptake in skeletal muscle and other tissues. This in turn results 
in increased levels of glucose in the blood. The onset of type 2 diabetes mellitus occurs 
commonly in adulthood and is silent and gradual, meaning it is common for the disease to 
remain undiagnosed for many years. Genetic, environmental, and lifestyle factors have been 
described which contribute to the development of type 2 diabetes mellitus (11, 14). Most 
genes associated to type 2 diabetes mellitus are linked to insulin production or secretion, 
or have so far an unclear function. Among the life style risk factors, overweight and/or low 
levels of physical activity are strongly associated with the development of type 2 diabetes 
mellitus (11, 15). Moderate or high levels of physical activity, weight reduction and coffee 
intake have been shown to mediate protective effects (16-18). 
The treatment of type 2 diabetes mellitus is focused on lifestyle changes and medication, 
with the drug of choice being metformin (19). Recently, there has been a debate whether 
intensive treatment with classic glucose lowering drugs improves cardiovascular outcomes in 
patients with diabetes. Recently developed pharmacological agents like glucagon-like peptide 
1 agonists and sodium-glucose co-transporter-2 inhibitors have been shown to be associated 
with a reduction of a composite outcome including death from cardiovascular causes, nonfatal 
myocardial infarction, or nonfatal stroke (20, 21). However, evidence suggests that the 
classical paradigm of a glucose lowering regime is not sufficient to reduce cardiovascular 
mortality. The UK Prospective Diabetes Study (UKPDS 33) showed a reduced relative risk of 
developing microvascular complications in the intensively treated group compared to standard 
treatment (22). By contrast, there were no change in mortality and a non-significant reduction 
in myocardial infarctions (p=0.052). A follow-up study, UKPDS 34, showed a reduced 
frequency of cardiovascular events (23). Hence, newly diagnosed diabetes seems to gain from 
intensive treatment. However, for patients that have had diabetes for a longer time the evidence 
for beneficial effect on cardiovascular outcome with intensive glucose lowering treatment 
are less clear (24). The limited effect of glucose lowering therapy alone on cardiovascular 
complications suggests that new mechanisms behind vascular complications in patients with 
type 2 diabetes mellitus need to be identified and explored. In the following pages this thesis 
will focus on type 2 diabetes mellitus which henceforth will be referred to as diabetes. 
The link between diabetes and cardiovascular disease 
Diabetes is associated with microvascular and macrovascular complications. Microvascular 
complications include nephropathy (vascular damage in the kidneys), retinopathy (vascular 
damage in the eyes), and neuropathy (mainly in peripheral nerves, causing sensations of 
numbness, pain, or buzzing in extremities). These complications may eventually progress to 
blindness, renal failure, and amputation of extremities. Macrovascular complications refer 
to myocardial infarction, stroke, or intermittent claudication. Cardiovascular disease is the 
main cause of death in patients with diabetes, with 50% estimated to die from macrovascular 
complications (25). Among patients with CAD, 30% have been shown to have diabetes and 
an additional 35% have impaired glucose intolerance (26). Patients with diabetes had three 
times higher risk for cardiovascular mortality than patients with without diabetes (27, 28). 
Furthermore, hypertension and hyperlipidemia commonly co-exists with diabetes (29). These 
findings constitute a clear link between diabetes and cardiovascular disease. 
       Arginase inhibition improves endothelial dysfunction
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The vasculature
There are three different blood vessels in the human body: arteries transporting blood away 
from the heart towards the body’s organs, veins transporting blood back to the heart, and 
capillaries in which the exchange of oxygen and nutrients take place at the organ tissue level. 
The main objective of the vasculature is to transport oxygenated blood, carried by red blood 
cells, to distal tissues where oxygen and waste products from cell metabolism are exchanged. 
These red blood cells are then transported back to the lungs to be re-oxygenated. If the red 
blood cells are the cargo trucks of the body the vasculature can be considered the highway. 
A blood vessel can be divided anatomically into three parts, the adventitia, the media and the 
endothelium. The external layer, the adventitia, is mostly constructed from connective tissue 
whereas the media consists mainly from smooth muscle cells. The vascular endothelium is 
a monolayer of cells, separating the circulating blood from the vessel wall. The endothelial 
layer is estimated to contain 1013 cells and, in the human, if spread out flat hypothetically 
would cover 1000 m2 (30). For many years the vascular endothelium was only considered to 
be a semi-permeable barrier with the sole purpose of keeping the blood circulating without 
unnecessary leakage. This simple concept of endothelial function has changed dramatically 
over the last 30 years and is the focus of this thesis.
The endothelium and endothelial function
A new area of research was introduced with the discovery that vasodilatation could be elicited 
by an endothelium-derived factor (31). With time, many other critical capabilities were 
discovered and the endothelium gained acceptance as a key regulator of vascular homeostasis. 
The endothelium produces substances affecting inflammation, thrombosis, and vascular tone. 
It is crucial that the endothelium maintains a proper balance between substances affecting 
these properties. Endothelial dysfunction is an imbalance of substances produced by the 
endothelium leading to disturbed homeostasis and eventually atherosclerosis. Nitric oxide 
(NO) is a molecule, produced by the endothelium, which mediates vasodilation, and has both 
anti-inflammatory, and anti-coagulant properties. However, during conditions of reduced 
bioavailability of NO, the positive actions mediated by this reactive molecule are diminished 
(32), initiating endothelial dysfunction (Figure 2). Taken together, the endothelium plays an 
important part in maintaining homeostasis by balancing vascular tone, inflammation, and 
coagulation. 
Endothelial dysfunction is central for the pathogenesis of atherosclerosis (33) and its risk 
factors diabetes (34) and hyperlipidemia (35). Endothelial dysfunction is associated with 
clinical events in patients with atherosclerosis and diabetes (9, 36). As illustrated in Figure 1, 
evidence suggests that endothelial dysfunction occurs early in the process of atherosclerosis 
and may amplify the progression and the poor prognosis of the disease (9, 10). 
As mentioned above, the pathology behind endothelial dysfunction is a reduction in the 
bioavailability of NO. In the endothelium, NO is produced together with citrulline from 
L-arginine by the enzyme endothelial NO synthase (eNOS) (37). Initially, NOS hydrolyses 
L-arginine to N-hydroxy-L-arginine, which is oxidized to citrulline and NO in a second step 
(38). One important mechanism of endothelial dysfunction is thus the lack of substrate for 
eNOS, L-arginine. There are three main forms of NOS enzymes. These are eNOS, neuronal 
NOS (nNOS) and inducible NOS (iNOS). eNOS and nNOS are constitutively expressed by a 
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wide range of cells. eNOS is mainly expressed in endothelial cells whereas nNOS mainly is 
expressed by neurons. The activity of the constitutive isoform is regulated by the intracellular 
concentration of Ca2+. During conditions of increased Ca2+ the co-factor calmodulin increases 
its affinity for eNOS/nNOS, hence facilitating the electron transport which is crucial for 
the function of the enzyme (39). Furthermore, the activity of eNOS is regulated by 
phosphorylation, targeting mainly the sites Ser1177 and Thr495, yielding additional and reduced 
activity, respectively. In the resting state, Ser1177 is usually not phosphorylated, however, in 
response to insulin, estrogen, sheer stress, or bradykinin it becomes phosphorylated by the 
activation of different kinases. Phosphorylated Ser1177 mediates its response by increasing the 
electron transport and increasing Ca2+-sensitivity (40, 41). On the other hand, phosphorylation 
of Thr495 inhibits the function of eNOS (39). iNOS is expressed by inflammatory cells and is 
regulated at the transcriptional level (42) and is Ca2+-independent (43). 
Decreased bioavailability of NO, defined as reduced concentration of NO available 
for mediating a biological response, is caused either by reduced production or increased 
inactivation of NO. The reasons behind inactivation and reduced production are multifactorial 
(Figure 3). Examples of molecular mechanisms are decreased co-factors, phosphorylation, 
production of ROS, and decreased substrate (44). Furthermore, one or several of these 
mechanisms may lead to the uncoupling of eNOS. Under conditions of oxidative stress and 
reduced levels of the important substrate L-arginine or the co-factor tetrahydrobiopterin 
(BH4), eNOS may produce the ROS superoxide (O2
-) from O2
 instead of NO from L-arginine 
(44). ROS might also be produced from other sources such as xanthine oxidase, NADPH 
Imbalance in the 
endothelium
Balance in the 
endothelium
Thrombosis
Inflammation
Vasoconstriction
Anti-thrombotic 
properties
Anti-
inflammation
Vasodilatation
Endothelial function Endothelial dysfunction
NO
PGI2
EDHF
NO
PGI2
EDHF
Angiotensin II
Endothelin
Thromboxane A2
Angiotensin II
Endothelin
Thromboxane A2
Figure 2. A schematic figure describing in general the delicate balance between endothelial factors 
regulating endothelial function. Nitric oxide (NO) is responsible for multiple positive actions in 
the endothelium. If NO bioavailability decreases, there is increased activation of vasoconstriction, 
inflammation and thrombosis. EDHF, endothelium-derived hyperpolarizing factor; NO, nitric oxide; 
PGI2; prostacyclin.
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oxidases, and the mitochondrial respiratory chain (45). NO and O2
- may react and form 
peroxynitrite (ONOO-), an extremely reactive and cytotoxic compound (44). It is rapidly 
protonated and forms peroxynitrous acid. On exiting the cell, due to the concentration 
gradient, peroxynitrous acid undergoes a cleavage and forms hydroxyl and nitric dioxide 
two highly reactive oxygen species. Both of these compounds play a central role in oxidative 
stress leading to reduction of BH4, further uncoupling eNOS producing more ROS (44). 
Oxidative stress therefore reduces active NO by: 1) superoxide reacting with NO itself, 
decreasing the free concentration of NO and 2) decreasing the cofactors, thereby mediating 
eNOS uncoupling and more ROS production.
Diabetes, hypercholesterolemia, and endothelial dysfunction
As mentioned above diabetes is associated with a substantial risk for cardiovascular disease 
(8). Existing data indicate that endothelial dysfunction is an important mediator in the 
Figure 3. Intact nitric oxide (NO) signalling is vital for homeostasis in the cardiovascular system through 
the regulation of vascular tone, platelet aggregation and cardiac function. Several risk factors (brown 
boxes) for cardiovascular disease promote processes (green boxes) that ultimately lead to a decrease 
in NO bioavailability. This occurs through enhanced NO degradation, attenuation of NO synthesis or 
desensitization of downstream NO signalling. eNOS, endothelial NOS; NOS, nitric oxide synthase. 
Figure and legend reproduced from (159). Permission obtained from Nature Publishing Group.
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development of cardiovascular complications in diabetes (36) and that these complications 
are a major cause of mortality among patients with diabetes (46). Suggested mechanisms 
behind the development of cardiovascular disease in patients with diabetes include pro-
inflammatory activation, reduced fibrinolytic capacity, and reduced platelet function (47, 48). 
Important triggers of these changes are hyperglycemia, hyperlipidemia, and oxidative stress 
leading to endothelial dysfunction (34). Hyperglycemia, insulin-resistance and elevated free 
fatty acids have been show to inhibit NO formation (34) and increase ROS formation (49). The 
vasoconstrictor and pro-inflammatory peptide endothelin-1 is produced in hyperinsulinemia 
(50) and hyperglycemia (51). Taken together, impaired NO-mediated vasodilatation and 
increased endothelin-1 has been observed in patient with diabetes (52). These processes 
influence the balance and function of the endothelium to promote vasoconstriction and 
inflammation. 
Hyperlipidemia in the form of hypercholesterolemia is an independent risk factor for 
cardiovascular disease and is also common in patients with diabetes (53). It is described that 
patients with hypercholesterolemia have impaired endothelial function both in the absence 
and presence of developed CAD (35, 54, 55). Accordingly, endothelial dysfunction is an 
early event observed in patients with familial hypercholesterolemia (FH) (56-58). Elevated 
low-density lipoprotein (LDL) cholesterol is an important risk factor for the development of 
atherosclerosis and CAD (53). FH is a genetic disorder characterized by high levels of total 
and particularly LDL cholesterol resulting in the premature development of atherosclerosis 
and its vascular complications including CAD (59). There is no elevation in the absolute 
number of LDL particles in patients with diabetes compared to patients without diabetes 
(60). However, the LDL particle in patients with diabetes is more dense (61), is more likely 
to undergo oxidative alterations (60) and is more easily taken up by smooth muscle cells and 
monocytes (62). Further, LDL particles in patients with type 2 diabetes are glycated (63). 
These qualitative modifications of LDL amplify the atherosclerotic process in diabetes (64).
Reperfusion injury  
A clinical complication of coronary artery atherosclerosis is plaque rupture, coronary artery 
occlusion, and development of acute myocardial infarction. Standard treatment of ST-
elevation myocardial infarction (a complete occlusion of blood flow in a coronary artery 
supplying the myocardium) is based on rapid reperfusion of the occluded coronary artery 
using either percutaneous coronary intervention or thrombolysis. Such treatments have 
led to limitation of myocardial injury and improved survival. However, reperfusion per se 
is associated with cellular injury contributing to the final vascular and myocardial injury 
(65). Ischemia-reperfusion (IR) injury has gained much interest as a main element of the 
total damage resulting from an acute myocardial infarction. Experimental studies have 
demonstrated that it is possible to preserve up to 50% of the area at risk in the myocardium 
by reducing IR injury (66). The mechanisms behind the IR injury involve several factors 
such as endothelial dysfunction, increased pro-inflammatory activity, increased formation of 
ROS, elevation of intracellular Ca2+, and opening of mitochondrial permeability transition 
pores (65), all of which contribute to the total myocardial injury. Endothelial dysfunction 
is suggested to be one key event in the development of IR (67) as the bioavailability NO 
is of importance for the protection against IR injury (32). Administration of NO-donor 
increased the bioavailability of NO and decreased infarct size in mouse hearts. The reduction 
in infarct size was abolished by co-administration of an NO-scavenger (68), emphasizing the 
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importance of NO for cardioprotection. As arginase regulates the bioavailability of NO and 
arginase inhibition has been shown to decrease infarct size in the experimental setting (66, 
69), inhibition of arginase might be of importance for cardioprotection in IR injury. However, 
no studies have evaluated arginase inhibition in the clinical setting. Many interventions have 
been suggested to reduce IR injury, and experimental studies have been promising. However, 
the translation into the clinic has been, in general, disappointing and many clinical studies 
have failed to demonstrate a reduction in infarct size in patients with ST-elevation myocardial 
infarction. Therefore, there is currently no intervention to reduce IR injury in clinical use.  
Arginase and cardiovascular disease
As described above, the mechanisms behind the reduction of the bioavailability of NO 
are complex, including both decreased production and increased elimination of NO. One 
mechanism that has generated much interest is increased activity of the enzyme arginase, 
which metabolizes the NO substrate L-arginine to ornithine and urea (Figure 4). Arginase 
Figure 4. A schematic illustration of the interaction between eNOS and arginase. Arginase metabolizes 
the same substrate as eNOS, L-arginine, and is up-regulated in response to different stimuli (white 
boxes). During conditions of reduced availability co-factors or substrate eNOS produce ROS 
which further could up-regulate arginase and decrease the ability for eNOS to produce NO. Ang II; 
angiotensin II, eNOS; endothelial nitric oxide synthase; H2O2, hydrogen peroxide; IL, interleukin; 
LPS, lipopolysaccharide; oxLDL, oxidized low-density lipoprotein; NO, nitric oxide; O2; superoxide, 
NADPHox, nicotinamide adenine dinucleotide phosphate-oxidase; ONOO, peroxynitrite; TNF-α, 
tumor necrosis factor- α; VSMC, vascular smooth muscle cells. Reproduced from (73). Permission 
obtained from Oxford University Press.
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is abundant in the liver where it plays a key role in the urea cycle, eliminating ammonia 
from the amino acid metabolism, but it is also expressed throughout the cardiovascular 
system (70). Two different isoforms of arginase have been identified. Arginase I is mainly 
expressed in the liver where it hydrolyses L-arginine as a part of the urea cycle. The other 
isoform, arginase II, is a mitochondrial protein expressed mostly in extra-hepatic tissues 
(70). The arginase enzymes share 50% of their amino acids, and their amino acid sequence 
is the same in areas vital for their enzymatic function (71) although they are coded from two 
different genes. Recent research has established that both arginase I and II are expressed in 
the cardiovascular system such as endothelial and vascular smooth muscle cells of blood 
vessels, and in cardiomyocytes (70, 72). However, the role of arginase in the cardiovascular 
system is incompletely understood and the expression of arginase differs between species 
and between different vascular beds (73). Arginase reciprocally regulates NO-production 
by using the same substrate and thereby reduces the availability of L-arginine for eNOS, 
reducing NO production and mediates endothelial dysfunction. Furthermore, arginase 
represses the translation and stability of iNOS (74, 75). Depletion of L-arginine also leads to 
the uncoupling of eNOS which results in ROS production (76), further enforcing this vicious 
cycle of ROS and reduced NO. Thus, arginase may contribute to impaired bioavailability of 
NO both by reducing the production of NO from L-arginine and by facilitating the inactivation 
of NO via increased formation of ROS. Vascular arginase has been described as being up-
regulated by cardiovascular risk factors such as hyperglycemia and LDL cholesterol resulting 
in increased arginase activity in atherosclerosis, myocardial ischemia and reperfusion and 
diabetes (66, 77-81). 
Expression and activity of arginase 
Arginase has gained much interest in the cardiovascular field as a regulator of endothelial 
function. Multiple factors involved in cardiovascular disease are known to modulate the 
activity or expression of arginase. Inflammation is of key importance in both atherosclerosis 
and diabetes. Tumor necrosis factor, interleukin-4, and interleukin-13 have been show to 
increase arginase activity (82, 83). This is further supported by the fact that arginase activity 
and expression of arginase I were up-regulated in a mouse model of endotoxin-induced uveitis 
(84). In humans, patients with inflammatory bowel disease have increased levels of arginase 
(85). ROS and peroxynitrite have been shown to increase arginase (86-88), suggesting an 
important regulatory action of oxidative stress. This is of interest considering that uncoupled 
eNOS produces ROS, which easily reacts with NO and forms peroxynitrite. 
Accumulating evidence suggest important links between LDL and arginase. In cell and rat 
experiments, oxidized LDL (oxLDL) particles have the potential of increasing arginase 
through activation of the RhoA/ROCK-pathway by upstream activation of lectin-like 
oxidized low-density lipoprotein receptor 1 (LOX-1) (89). The same study observed that 
inhibition of ROCK reduced the increase in arginase after oxLDL stimulation. Furthermore, 
oxLDL induced Rho translocation and activation, which could be prevented with a LOX-
1 antibody or statins. Rho silencing or Rho-kinase inhibition reduced oxLDL-stimulated 
arginase II activation (89). Additional studies have demonstrated reduced arginase expression 
after inhibition of RhoA and ROCK, suggesting that this pathway could be importance in the 
regulation of arginase (85). In an experimental models of atherosclerosis, e.g. apolipoprotein 
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E knockout mice, arginase II was increased compared to control animals (90). This is in line 
with the results of similar work of the same animal model (91, 92). Rabbits fed cholesterol 
rich diet have increased expression of both isoforms of arginase (93). In humans, it has been 
demonstrated that maternal hypercholesterolemia in pregnancy is associated with increased 
arginase expression and activity in the umbilical vein accompanied with reduced eNOS 
activity (94). Taken together, up-regulation of arginase is present during LDL exposure and 
one pathway could be activation of LOX-1 and RhoA/ROCK.
Glucose has been shown to increase arginase (95), which is of interest considering the 
important role of endothelial dysfunction in diabetes. In experimental models of diabetes 
arginase activity and arginase I expression were increased in aorta (78). Furthermore, the 
impairment in endothelial function correlated with arginase activity and production of ROS 
(78). Expression of arginase is increased in aorta and myocardium of rats with diabetes (77). 
Arginase II is involved in the reduced relaxation of corpus cavernosum in diabetic animals 
(96) and arginase expression was increased in corpus cavernosum in patients with diabetic 
erectile dysfunction (97). Reports from one clinical study show an up-regulation in plasma 
arginase in addition to a reduced NOS activity in patients with diabetes (81). Another recent 
study observed up-regulation of arginase I in coronary arterioles from patients with diabetes, 
and that arginase contributes to the reduced NO-production in vitro (98). Hence, arginase 
seems to be of importance in the experimental and possibly in the clinical setting of diabetes.
In an experimental model of IR injury, arginase expression was increase in coronary 
endothelial cell and smooth muscle cells (99). Similarly, the expression of arginase I is 
increased in ischemic myocardium (66). Increased arginase activity has also been shown 
in patients with myocardial infarction and this change correlated with the area of necrosis 
(100, 101). The activity of arginase increased in infarcted myocardium compared to normal 
myocardium. Furthermore, an increased concentration of urea on the venous side compared to 
arterial was observed, suggesting a local production of urea by arginase (102). Other factors 
contributing to increase arginase activity is hypoxia (103), relevant in IR (66), angiotensin 
(104) and thrombin (90). 
 
These observations suggest that arginase is up-regulated in settings of inflammation, 
hyperlipidemia, atherosclerosis, diabetes, and myocardial IR. 
Functional role of arginase 
Based on the experimental evidence demonstrating increased arginase activity and reduced NO 
bioavailability in several cardiovascular disease conditions, studies using arginase inhibitors 
have been performed to evaluate the functional role of arginase in vivo. Experimental studies 
have described improvements in endothelial function by inhibiting arginase in various 
experimental models of cardiovascular disease including atherosclerosis, hypertension 
and diabetes type 1 and type 2 (73). Arginase inhibition restored endothelial function in 
hypertensive rats (105, 106). NO production and endothelium-dependent vasodilatation was 
increased following silencing of arginase I in rat aortas (79). Another experiment evaluated 
endothelial function and vascular stiffness in old rats. It was shown that arginase activity 
was higher in old rats compare to young and that arginase inhibition improved endothelial 
function, vascular compliance, and reduced NOS uncoupling in the old rats (107). Rings 
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from rat aortas incubated with oxLDL decreased NO metabolites production and increased 
arginase activity. These changes were reversed by arginase inhibition (108). The same study 
also showed a time-dependent increase of arginase in human aortic endothelial cells exposed 
to oxLDL. Arginase II inhibition or deletion of the arginase II gene prevented the decreased 
in NO levels, ROS production, vascular stiffness, and restored endothelial function (91). 
Experimental evidence also suggest an important functional role of arginase in diabetes. 
Arginase inhibition reversed the impairment in endothelium-dependent vasodilation in 
coronary arteries in diabetic rats (78). Rats with diabetes had reduced coronary flow reserve 
compared to healthy rats in vivo (77). Arginase inhibition restored coronary flow reserve in 
diabetic animals to levels seen in healthy animals (77). Furthermore, expression and amino 
acid analyses suggested that arginase is up-regulated in diabetic animals (77). Together, this 
suggests that arginase is of importance for microvascular dysfunction in rats with diabetes. 
Furthermore, the positive effect of arginase inhibition was abolished by co-administration 
of a NOS-inhibitor, suggesting the effect of arginase inhibition is mediated by NOS (77). In 
the same paper arginase II expression was increased in aorta and myocardium in rats with 
diabetes, and the citrulline/ornithine ratios, reflecting the indirect measurement of NOS versus 
arginase activity, increased more in the diabetes group after intervention. These observations 
offer further support to the idea that arginase is of importance for vascular homeostasis. 
Even though there are multiple studies evaluating the acute effect of arginase inhibition the 
long-term effects of this intervention is largely unknown. One study exposed spontaneously 
hypertensive rats to ten weeks of arginase inhibition which resulted in antihypertensive effect 
and prevention of remodeling of the aorta and myocardial fibrosis without any reported 
side effects (109). This indicates that arginase inhibition could have effect on long-term 
remodeling, which could be positive in the treatment of cardiovascular disease. 
Data from clinical studies on patients with cardiovascular disease are sparse. These are 
limited to ex vivo studies on coronary arterioles obtained from patients with diabetes (98) 
and in vivo where subcutaneous administration by microdialysis of arginase inhibitor to 
patients with hypertension showed attenuation of cutaneous vasodilatation in hypertensive 
subjects (110). In contrast, L-arginine supplementation failed to generate a positive effect 
on this outcome. The same investigator showed that arginase inhibition administered 
by microdialysis improved cutaneous vasodilatation in old humans compared to young 
individuals (111). These studies suggest that arginase inhibition improves vascular function 
under these conditions. 
Since arginase is upregulated, and NO bioavailability is reduced during myocardial IR, 
previous studies have investigated the pathophysiological role of arginase in the setting of 
myocardial IR. In a rat model of 30 minutes coronary artery ligation followed by two hours 
reperfusion it was shown that administration of the arginase inhibitor Nω-hydroxy-L-arginine 
(nor-NOHA) 15 minutes before ischemia reduced infarct size by approximately 50% (66). 
This cardioprotective effect was abolished after co-administration of the NOS-inhibitor 
L-NG-monomethyl arginine (L-NMMA) suggesting the effects of arginase inhibition is 
mediated by NOS (66, 77). Diabetic and non-diabetic rats demonstrated reduced infarct size 
after administration of arginase inhibition in an experimental model of myocardial infarction 
(112). This is of importance considering the up-regulation of arginase in diabetes and in IR 
(113), the poor outcome of patients with diabetes suffering from myocardial infarction (60), 
and the unfavorable outcome after revascularization among patients with diabetes (114, 115). 
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Diabetes contributes to an unfavorable milieu after IR by promoting endothelial dysfunction, 
alteration of neutrophil infiltration, and reduced eNOS function (114). Hence, it is of great 
importance to evaluate arginase inhibition in the setting of IR in subjects with diabetes.
Collectively, available data suggest that arginase plays and important role in cardiovascular 
disease and that targeting arginase activity may be a promising novel therapeutic strategy. 
However, no in vivo data is available regarding the efficacy of arginase inhibition to improve 
endothelial function in patients with risk factors such as diabetes or clinically apparent CAD. 
Based on the above mentioned experimental data arginase inhibition could be of clinical 
benefit in the condition of diabetes, hypercholesterolemia, or IR. 
Treatments restoring the bioavailability NO have shown promising results in experimental 
studies. However, many of the therapies have failed to prove successful in the clinical setting. 
In addition, traditional intensive glucose lowering therapy does not seem to decrease the 
mortality from cardiovascular disease in patients with diabetes, suggesting new mechanisms 
should be explored. Furthermore, today there are no drugs specifically targeting the 
molecular mechanisms behind endothelial dysfunction in patients with diabetes, CAD, or 
hypercholesterolemia. This thesis will evaluate the functional significance of inhibiting 
arginase for endothelial function in patients with glucose and lipid abnormalities.
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The objective was to test the hypothesis that the enzyme arginase plays a key role in the 
development of micro- and macrovascular dysfunction in patients with glucometabolic 
disorders by reducing the bioavailability of NO. This hypothesis was tested in interventional 
studies using arginase inhibition in patients with type 2 diabetes and hypercholesterolemia 
with and without clinically apparent cardiovascular disease.
The specific aims were:
1. To investigate the effect of arginase inhibition on peripheral endothelial function in 
patients with CAD and type 2 diabetes. 
2. To investigate the therapeutic effect of arginase inhibition on microvascular func-
tion in type 2 diabetes.
3. To evaluate the effect of arginase inhibition on IR-induced endothelial dysfunction 
in CAD and type 2 diabetes.
4. To investigate the regulatory role of arginase on endothelial function in patients with 
hypercholesterolemia.
OBJECTIVE AND AIMS
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Study subjects
All study subjects were recruited from Karolinska University Hospital. These studies 
were conducted according to the declaration of Helsinki and approved by the local ethical 
committee. Study subjects were informed about the possible harm and all subjects gave 
their oral and written consent. All subjects tolerated the study protocols well. 
General exclusion criteria were a) participation in another ongoing study b) unwillingness 
to participate c) myocardial infarction or instable angina within three months d) disease or 
condition that reduced the patients’ ability to complete the study protocol e) arterio-venous 
shunts f) other vascular anomalies, such as Raynauds phenomenon g) age > 80 years h) 
ongoing treatment with oral anticoagulants. 
Study I
In Study I, 16 patients with CAD, defined as 50% stenosis on coronary angiography or 
previous medical history of myocardial infarction, were included. In addition, 16 patients 
with both CAD and diabetes were included. Diabetes was defined as two occasions of 
elevated fasting glucose of above 7.0 mmol/l or levels exceeding 11.0 mmol/l 2 hours after 
75 g of an oral glucose load. All patients were recruited from the Department of Cardiology 
at Karolinska University Hospital. The control group consisted of age-matched subjects 
without medications and history of cardiovascular disease. The control group was screened 
by an exercise tolerance test and an oral glucose tolerance test. 
Study II
Patients were recruited from the Department of Endocrinology, Metabolism and Diabetology 
at Karolinska University Hospital. Patients with diabetes and microvascular dysfunction 
were included. Diabetes was defined as above and microvascular dysfunction was defined 
as either retinopathy or microalbuminuria > 3.0 mg/mmol. Furthermore, a control group of 
12 healthy age-match controls was recruited. 
Study III
Patients were recruited from the Department of Cardiology at Karolinska University 
Hospital. Twelve subjects with CAD and 12 subjects with both CAD and diabetes were 
included. Inclusion criteria were as in Study I. 
Study IV
Twelve patients with FH were recruited from the Department of Endocrinology, 
Metabolism and Diabetology or the Department of Cardiology at Karolinska University 
Hospital. An age-matched control group without medications, history of cardiovascular 
disease, or history of diabetes was recruited. The FH diagnosis was determined by the 
Dutch Lipid Clinic Network criteria (116). Exclusion criteria were clinical symptom or 
history of cardiovascular disease, hypertension, diabetes, excessive alcohol consumption, 
or microalbuminuria. 
METHODS
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Measurement of endothelial function
In general, all techniques for evaluating endothelial function consist of two parts 1) a 
technique to measure blood flow or vessel diameter and 2) stimulation of the endothelium 
by pharmacologic agents (serotonin or acetylcholine) or by increased shear stress. This 
increase in blood flow or vessel diameter in response to an endothelium-specific stimulus 
is referred to as endothelium-dependent vasodilatation (EDV) and is the result of NO 
produced by the endothelium. Endothelium-independent vasodilatation (EIDV) is the 
increase in blood flow during administration of an NO donor which acts on the smooth 
muscle cells directly without involving the endothelium. 
Venous occlusion plethysmography
Venous occlusion plethysmography is a method for evaluating the arterial inflow into the 
forearm. It was used in Study I and IV. The blood flow was measured by placing a strain-
gauge (a device measuring the change in circumference) around the widest part of forearm. 
The change in circumference results in a change of volume which is related to arterial 
flow rate. For this measurement set-up, two blood pressure cuffs were placed on each 
arm, one at the level of the upper arm and one at the level of the wrist. The proximal cuff 
was inflated to 50 mmHg to stop venous blood from exiting the arm but allowing entry of 
arterial blood. The cuff at the wrist was inflated to 30 mmHg above systolic pressure to 
exclude the complex circulation of the hand. The proximal cuff was inflated in cycles of 
ten seconds during which the arm circumference increased (due to arterial blood entering 
the arm) followed by release of the cuff for five seconds during which the circumference 
returned to baseline. This procedure was performed eight times during each infusion of 
either saline, serotonin, or sodium-nitroprusside (SNP) (Figure 5). The clinical use of 
this method originally was to evaluate a clinical diagnosis of venous thrombosis. Over 
time, great knowledge of human physiology has been shared among clinicians in many 
generations (117). 
Flow mediated vasodilatation
Flow mediated vasodilatation (FMD) is a method based on ultrasound, using a high 
frequency (11 MHz) linear ultrasound probe placed over an artery to record the diameter 
of the vessel, usually the radial or brachial artery. The diameter of the vessel is recorded 
before and after a period of 5 minutes of local ischemia to the arm using a blood pressure 
cuff placed on the forearm and inflated to 30 mmHg above systolic pressure. The hyperemia 
occurring following deflation of the cuff increases the sheer stress to the endothelium. 
Shear stress stimulates the endothelium to produce NO, which mediates dilatation of the 
artery detected by ultrasound and is a measurement of endothelial function (Figure 6). The 
diameters are recorded in the same time point in each cardiac cycle to generate comparable 
data. This method was used in Study III, in which we evaluated the radial artery in the 
non-dominant arm using an 11 MHz transducer connected to a Vivid E9®. Images were 
recorded every third second at end diastole. A tripod was used to minimize any movement 
artefact. Baseline measurement was recorded as the mean of 20 frames. The effect size for 
the experiment was a ratio of the mean diameter of the three highest values after ischemia 
divided by the mean diameter recorded at baseline. 
       Arginase inhibition improves endothelial dysfunction
25
Figure 5. Recordings from investigation with venous occlusion plethysmography. The circumference 
of the forearm is recorded in active (red curves) and control arm (green curves). The circumference 
increases when the blood pressure cuffs are inflated (yellow line). By placing a tangent in lining 
with the increase in diameter (black tangent in the middle figure) in the four steepest curves, forearm 
blood flow was calculated. A set of eight curves were recorded over a period of 2 minutes. Baseline 
forearm blood flow is evaluated during saline administration (top figure). Endothelium-dependent 
vasodilatation is stimulated with serotonin. The middle panel demonstrates the response in forearm 
blood flow to the highest concentration of serotonin. Endothelium-independent vasodilatation is 
stimulated with sodium-nitroprusside (bottom). NaCl, saline; Ser 210, serotonin 210 ng/min; SNP 10, 
sodium-nitroprusside 10 µg/min.
NaCl
SNP 10
Ser 210
Active arm
Control arm
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Laser Doppler flowmetry and iontophoresis  
Laser Doppler flowmetry (LDF) is, in essence, a laser beam that projects onto the skin and 
is reflected by red blood cells within the cutaneous microcirculation. This method is used 
to estimate indirectly blood flow in the microvasculature. As the technique just reflects the 
amount of red blood cells at one point in the skin, it is not possible to estimate actual blood 
flow and instead an arbitrary measure of flow is obtained. The probes containing the laser 
Doppler also have the ability to deliver substances locally to the skin. By doing so it is possible 
to investigate the EDV by administering acetylcholine and the EIDV with SNP within the 
microcirculation. Acetylcholine and SNP are delivered into the skin using iontophoresis i.e. 
by using an electrical current. This method was used in Study II. Two probes were placed 
on the subjects arm 5 cm apart. After the baseline flow had been recorded for 3 minutes, 
acetylcholine and SNP were administered simultaneously using currents of 0.08, 0.14, and 
0.20 mA. Each of the three stimulations was maintained for one minute and then recorded 
for 15 min to ensure the maximum response for each substance.
(Diameter after reactive hyperemia – Baseline diameter) 
/ Baseline diameter
= 
FMD
Baseline diameter Diameter after reactive 
hyperemia
5 min 
ischemia
Baseline
diameter Diameter after
reactive hyperemia
Sekunder
Figure 6. Flow-mediated vasodilatation recordings. Baseline artery diameter is recorded with an 
automated edge detection (picture top left). After 5 minutes local ischemia, reactive hyperemia is induced 
by decreased resistance after ischemia, new frames were recorded (top right). The dilatation is visualized 
in the lower figure where baseline and maximal artery diameters are presented. Frames are recorded at 
end-diastole every third second during the period of measurement. FMD; flow-mediated vasodilatation.  
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Substances 
Nω-hydroxy-nor-L-arginine (Nor-NOHA) (Bachem, Bubendorf, Switzerland) and serotonin 
(Sigma-Aldrich, Schnelldorf, Germany), were dissolved in double-distilled water sterile 
filtered through a Milipore filter, tested for bacteria and toxins and frozen at – 80°C.  
Sodium nitroprusside (SNP, Abbot, Chicago) and L-N-monomethyl L-arginine (L-NMMA) 
(Clinalfa, Läufelfingen, Switerland) were diluted in 0.9 % saline to proper concentration on 
the day of the experiment.
Acetylcholine (Bausch & Lomb Nordic AB, Stockholm, Sweden) was diluted in 0.9% saline.
Nitroglycerine (0.4 mg, PharmaPol, Dägeling, Germany). 
Local anesthesia using Xylocaine 10 mg/ml (AstraZeneca, Sweden).
Study protocols
Blood samples were collected in the fasting state at the beginning of each protocol. 
Study I
Forearm blood flow (FBF) was recorded by venous occlusion plethysmography in both arms 
simultaneously. Following infiltration with local anesthesia, a catheter was introduced in the 
brachial artery of the non-dominant arm for i.a. infusions. A venous catheter was introduced 
in a deep cubital vein of the same arm to collect blood perfusing the forearm. Baseline FBF 
was recorded during a saline infusion of 3.5 ml/min. EDV and EIDV were recorded during 
infusion of 21, 70, and 210 ng/min for serotonin and 1, 3, and 10 µg/min for SNP at a rate 
of 2.5 ml/min together with 1 ml/min saline. After baseline EDV and EIDV were recorded, 
administration of nor-NOHA was started instead of saline and given at a rate of 0.1 mg/min 
(1 ml/min). Nor-NOHA was administered for 120 min, after which basal FBF, EDV, EIDV 
were evaluated again in the same manner. For a visual representation of the protocol, see 
Figure 7. Five patients with CAD and diabetes participated in one additional protocol. To 
examine if the effect of nor-NOHA was dependent on NOS, the NOS-inhibitor L-NMMA 
was co-administered with nor-NOHA at a rate of 2 mg/min (1 ml/min).  
NaCl 0.9% (60 ml/h) Nor-NOHA 0.1 mg/ml (60 ml/h)
120 min
Ser
ng/min
150 ml/h
NaCl
150 
ml/h
21 70 210 1 3 10
SNP
µg/min
150 ml/h
Ser
ng/min
150 ml/h
NaCl
150 
ml/h
21 70 210 1 3 10
SNP
µg/min
150 ml/h
Figure 7. The protocol of Study I. During the administration of i.a saline forearm blood flow was 
recorded during co-administration of serotonin (21, 70, and 210 ng/min) and sodium-nitroprusside (1, 
3, and 10 µg/min). Each infusion was maintained for 2 minutes. The same parameters were evaluated 
after 120 minutes i.a. administration of nor-NOHA (0.1 mg/min). NaCl, saline; nor-NOHA, Nω-
hydroxy-nor-L-arginine; Ser, serotonin; SNP, sodium-nitroprusside.
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Study II
Microvascular endothelial function was measured by LDF. Two probes containing drug 
delivery system and laser Doppler were placed on the subjects’ non-dominant forearm 5 
cm apart. Shallow veins, scars and discolorations was avoided. An arterial catheter was 
introduced in the brachial artery to administer saline and the arginase inhibitor nor-NOHA 
(0.1 mg/min). Acetylcholine and SNP to stimulate EDV and EIDV were administered 
simultaneously by iontophoresis using currents of 0.08, 0.14, and 0.20 mA each stimulus 
was maintained for 60 seconds. The microvascular response to these stimuli was recorded 
for 15 min after each stimulation. The evaluation of EDV and EIDV were evaluated before 
and after 120 min of nor-NOHA administration (Figure 8). 
Study III
Subjects with CAD with and without diabetes were subjected to two different protocols. 
Catheters were introduced into the brachial artery and a deep vein catheter of the non-
dominant arm. A vacuum cushion was used to reduce the movement of the arm. EDV was 
measured by FMD (see above) at baseline and after 40 minutes of IR, i.e. 20 minutes of 
ischemia and 20 minutes of reperfusion. During the two protocols, 0.9% NaCl or nor-NOHA 
(0.1 mg/min) were given as i.a. infusions at a rate of 1 ml/min. The infusions started 15 
minutes into the period of ischemia and were maintained for 20 minutes (Figure 9). The order 
of the protocols was randomized by blindly drawing one out of two numbers printed on two 
different pieces of paper.
FMD FMDIschemia NTG
0 15 20
’
35 40
’
Nor-NOHA/NaCl
60 ml/h, 20 min
NaCl 6 ml/h NaCl 6 ml/h
min
Figure 9. The protocol of Study III. FMD was evaluated at baseline and after 20 minutes of ischemia 
and 20 minutes of reperfusion. Either saline or nor-NOHA was given by i.a. infusions. All subjects 
performed the protocol twice. FMD; flow-mediated vasodilatation, nor-NOHA; nor-NOHA, Nω-
hydroxy-nor-L-arginine, NTG; nitroglycerine.  
NaCl 0.9% (60 ml/h) Nor-NOHA 0.1 mg/ml (60 ml/h)
120 min
Ach (20 mg/ml)
SNP (20 mg/ml)
0.20
mA
0.14
mA
0.08
mA
Ach (20 mg/ml)
SNP (20 mg/ml)
0.20
mA
0.14
mA
0.08
mA
Figure 8. The protocol of Study II. Laser Doppler flowmetry was measured during transcutaneous 
iontophoretic delivery of acetylcholine and sodium-nitroprusside (SNP) in three doses was 
administered during saline administration and again after 120 minutes of i.a. administration of 
nor-NOHA. Each stimulation was maintained for 60 seconds and recorded during 15 minutes. 
The concentration of acetylcholine and SNP was 20 mg/ml. Ach, acetylcholine; NaCl, saline; mA, 
milliampere; nor-NOHA, Nω-hydroxy-nor-L-arginine; SNP, sodium-nitroprusside.
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Study IV
In Study IV, patients with FH performed the protocol twice. During the first visit, FH subjects 
had stable medication with lipid-lowering drugs. All subjects were prescribed statins (n=12) 
and two had additional treatment with ezetimibe. After visit 1 all lipid-lowering drugs were 
discontinued for four weeks, after which the second visit was performed. Control subjects 
were evaluated once. The protocol was similar to that of Study I with the exception that 
the doses of serotonin used to evaluate EDV were reduced on the basis of a younger and 
healthier patient group and one extra dose was added. The doses of serotonin that were used 
were 5.25, 17.5, 52.5, and 175 ng/min. EIDV was evaluated by administration of SNP as in 
Study I. FBF, EDV, and EIDV were evaluated before and after 120 minutes of nor-NOHA 
administration (0.1 mg/min). 
Analysis of arginase expression and amino acids
Arginase expression was analyzed by immunohistochemistry. A small section of the left 
internal mammary artery was harvested from patients with stable CAD with and without 
diabetes undergoing coronary artery bypass grafting surgery. The distal end of the artery was 
sliced and frozen in dry ice. Samples were sectioned, fixed with acetone, and stained with 
MACH 3 technology (Biocare Medical). Primary antibodies against arginase I, arginase II, 
alpha-actin, and von Willebrand factor were incubated together with the sections for one 
hour at room temperature.
 
For determination of the amino acids L-arginine, ornithine, and citrulline, liquid 
chromatography tandem mass spectrometry was used (118). 
Statistical analysis 
In all studies, statistical analyses were performed with GraphPad Prism (Version 5.0/6.0 
GraphPad software Inc, La Jolla, CA, USA). 
Study I
We estimated that 12 subjects were sufficient to detect a significant improvement in EDV.
Study II
Based on a previous interventional study of microvascular function of comparable design 
(119) we estimated that 12 individuals were sufficient to detect a significant improvement in 
endothelium-dependent dilatation.
Study III
Based on an absolute improvement of FMD of 3% and a SD of 1.85%, the number of subjects 
needed to reach 80% power with a 2-sided test with a significance level of 5% was calculated 
to be 12.
Study IV
In Study I, we observed an improvement in EDV by a mean of 18 ml/min/1000 ml in 
patients with coronary artery disease and type 2 diabetes. Assuming an improvement of 
12 ml/min/1000 ml in the current population, we calculated that 11 individuals would be 
sufficient to reach 80% power with a 2-sided test with a significance level of 5%.
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The data from subject characteristics was normally distributed and was analyzed with 
Student’s t-test when comparing two groups. In the case of inclusion of three groups, as in 
Study I, unpaired one-way analysis of variance was used. 
In EDV and EIDV data contained repeated measurements before and after intervention of 
each subject and all studies included at least two groups. Comparison between baseline and 
after intervention within each group was performed using paired analysis whereas unpaired 
analysis was used for comparisons between groups. Two-way analysis of variance with 
repeated measurements was used to analyze the data. Basal blood flow (Studies I and IV) 
and radial artery diameter (Study III) were analyzed with one-way analysis of variance. 
Normal distribution of data was determined using the D’Agostino-Pearson normality test and 
plotted for visual evaluation.
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For patient characteristics and medications, please see tables 1 and 2 respectively. 
Study I
Patients with CAD and diabetes had significantly higher glucose and HbA1c levels than 
the other groups. No difference was observed regarding blood pressure. The patient groups 
had lower levels of cholesterol than the control group since they were on lipid-lowering 
medication (Tables 1 and 2). 
To determine the expression of arginase isoforms we stained for arginase I and II in the 
left internal mammary artery obtained from CAD patients with and without diabetes using 
immunohistochemistry. Both isoforms of arginase were expressed but at different locations 
in the vessel wall. Arginase I was expressed both in endothelial cells and in smooth muscle 
cells, whereas arginase II was expressed more selectively in endothelial cells (Figure 10). 
With the knowledge that arginase was expressed in arteries of patients with CAD with and 
without diabetes we proceeded with studies evaluating the functional importance of arginase. 
There were no significant differences in FBF at baseline between the groups. Further, 
administration of nor-NOHA did not affect baseline FBF in any of the groups. Patients with 
CAD had a reduced baseline EDV compared to healthy subjects (Figure 11, P<0.01). Patients 
with both CAD and diabetes had worse baseline EDV than patients with CAD alone (Figure 
11, P<0.01). Baseline EIDV was reduced in patients with CAD (P<0.05) and CAD and 
diabetes (P<0.01) compared to healthy subjects.
The role of arginase in regulation of endothelial function was tested by the administration of 
the arginase inhibitor nor-NOHA. This induced a significant increase in EDV in subjects with 
CAD and diabetes as well as in patients with CAD alone (Figure 11). By contrast, no increase 
in EDV was seen among healthy subjects after administration of nor-NOHA. Importantly, the 
improvement in EDV after nor-NOHA administration was greater in the CAD and diabetes 
group than in the CAD group (Figure 12). EIDV increased slightly in the CAD and diabetes 
group (P<0.001) following nor-NOHA administration, but it remained unchanged in the 
other two groups.
We investigated further whether NOS was involved in the improvement in EDV induced 
by arginase inhibition. Interestingly, the NOS inhibitor L-NMMA completely abolished the 
positive effect of nor-NOHA on EDV (Figure 13), suggesting that the effect of arginase 
inhibition was mediated via a NOS-dependent pathway. 
Study II
In light of our findings from Study I, i.e. that subjects with diabetes had a significantly greater 
improvement in endothelial function in response to arginase inhibition, we investigated if 
arginase was of importance for microvascular dysfunction in subjects with diabetes. 
The diabetes group had higher BMI, C-reactive protein, fasting glucose and HbA1c, but 
lower total, LDL and HDL cholesterol compared to the control group (Table 1). None of 
the subjects were smokers. Subjects in the control group did not take any medication. The 
medications of the groups are listed in Table 2.
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Table 2. Medication taken by subjects included in this thesis. Data are presented as absolute numbers. 
ACE inhibitors, angiotensin converting enzyme antagonists; ARB, angiotensin II receptor blocker; 
CAD, coronary artery disease; FH, familial hypercholesterolemia.
Study I Study II Study III Study IV
Controls 
(n=16)
CAD 
(n=16)
CAD+diabetes 
(n=16)
Controls 
(n=12)
Diabetes 
(n=12)
CAD 
(n=12)
CAD+diabetes 
(n=12)
Controls 
(n=12)
FH 
(n=12)
Visit
Medication (no.) 1st 2nd
Lipid-lowering drugs 0 12 15 0 9 11 10 0 12 0
ACE-inhibitors 
or ARB 0 9 8 0 10 8 10
Beta-blockers 0 14 12 0 5 11 8
Antiplatelet drugs 0 15 15 0 12 12 12
Calcium channel  
blockers 0 0 5 0 5 0 3
Diuretics 0 1 4 0 3 2 3
Nitrates 0 3 3 0 2 1 4
Oral glucose  
lowering drugs 0 0 9 0 7 0 8
Insulin 0 0 5 0 10 0 4
Arginase I
Arginase II
α-actin
von Willebrand factor
50 µm
50 µm 50 µm
50 µm
Figure 10. Immunohistochemical staining of left internal mammary artery from patient with CAD. 
Arginase expression is indicated in the figures to the left with black arrows. Expression of α-actin is 
used as marker for smooth muscle cells and von Willebrand factor for endothelial cells. Arginase I is 
present in both the endothelium and in the smooth muscle cells whereas arginase II is predominately 
expressed in the endothelium.  
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Figure 11. Results of endothelium-dependent vasodilatation (EDV) from Study I. EDV was not 
effected in the control group after arginase inhibition. However, arginase inhibition improved EDV in 
CAD subjects both with and without diabetes. Data is presented as mean ± SD. Significant differences 
between EDV following nor-NOHA in comparison with baseline EDV are presented. CAD, coronary 
artery disease; FBF, forearm blood flow; nor-NOHA, Nω-hydroxy-nor-L-arginine.
Figure 12. Change in EDV in response to 
arginase inhibition in patients with CAD and 
CAD and diabetes. The change was calculated 
as the difference in EDV between EDV during 
arginase inhibition and EDV at baseline. The 
improvement was greater in the CAD and 
diabetes group compared to patients with 
CAD only. Data are presented as mean ± SD. 
CAD, coronary artery disease; FBF, forearm 
blood flow; nor-NOHA, Nω-hydroxy-nor-L-
arginine.
Figure 13. To investigate the mechanism behind 
arginase inhibition patients with CAD and diabetes 
performed one additional protocol in which the 
NOS-inhibitor L-NNMA was administered. The 
change was calculated as the difference in EDV 
between EDV during arginase inhibition and EDV 
at baseline. The positive change in EDV was 
abolished after NOS-inhibition, suggesting that 
the improvement in EDV is NOS-dependent. Data 
are presented as mean ± SD. CAD, coronary artery 
disease; FBF, forearm blood flow; L-NMMA, 
L-NG-monomethyl arginine; nor-NOHA, Nω-
hydroxy-nor-L-arginine.
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To evaluate if basal microvascular endothelial function was reduced in subjects with diabetes 
we recorded the EDV response during saline administration. Baseline microvascular EDV 
(increase in flow evoked by acetylcholine) was reduced in patients with diabetes compared to 
healthy subjects (Figure 14). Interestingly, after nor-NOHA administration, EDV increased 
in the diabetes group (P<0.05) to the level observed in healthy subjects (Figure 14). EDV in 
the control group did not change in response to arginase inhibition. EIDV (increase in flow 
evoked by SNP) did not differ between the groups nor did it change significantly within each 
group in response to arginase inhibition. 
To quantify the relative activity between arginase and NOS, amino acid substrate and 
products of each enzyme were determined in plasma from healthy control subjects and 
patients with diabetes (Table 3). The arginase product ornithine was significantly higher 
among patients with diabetes than healthy subjects (71.3±28.1 vs. 50.0±8.2 µmol/L, P<0.05). 
The NOS product citrulline or the substrate L-arginine did not differ between the groups. 
Ratios was calculated to estimate the relative activity of NOS and arginase. Ornithine/L-
arginine and ornithine/citrulline ratios were elevated in patients with diabetes compared to 
control subjects (0.91±0.28 vs. 0.65±0.16, P<0.05 and 1.99±0.73 vs. 1.41±0.38, respectively, 
P<0.05), suggesting an increased arginase activity in subjects with diabetes. 
Table 3. Amino acid levels and ratios in Study II. Data are mean values ± SD. Significant differences 
between groups are shown: *P<0.05 vs. control subjects.
Amino acid (mmol/l) Controls (n=12) Type 2 diabetes (n=12)
Arginine 78.8 ± 14.4 79.2 ± 18.0
Ornithine 50.0 ± 8.2 71.3 ± 28.1*
Citrulline 37.9 ± 10.7 38.4 ± 13.7
Ratios
Ornithine/Arginine 0.65 ± 0.16 0.91 ± 0.28*
Ornithine/Citrulline 1.41 ± 0.38 1.99 ± 0.73*
Citrulline/Arginine 0.49 ± 0.13 0.49 ± 0.18
Figure 14. Microvascular endothelium-dependent and endothelium-independent function measured with 
laser Doppler flowmetry before and after 120 minutes i.a. administration of nor-NOHA. The diabetes 
group had reduced microvascular endothelial function at baseline compared to the control subjects 
(P<0.05). Arginase inhibition improved microvascular endothelial function in the diabetes group to the 
level of control subjects after intervention. Data are presented as mean ± SD. Ach, acetylcholine; mA, 
milliampere; nor-NOHA, Nω-hydroxy-nor-L-arginine; SNP, sodium-nitroprusside.  
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Study III
As mentioned above, up-regulation of arginase in may reduce NO bioavailability contributing 
to endothelial dysfunction and IR injury. Therefore, the aim of this study was to investigate 
if arginase inhibition protects from endothelial dysfunction induced by IR in patients with 
CAD. Furthermore, since arginase seemed to be of particular importance for endothelial 
dysfunction in patients with diabetes (Study I), a group of subjects with CAD+diabetes was 
included. 
Patients with CAD had lower fasting glucose and HbA1c than patients with both 
CAD+diabetes (Table 1). 
 
FMD, i.e. the endothelium-dependent increase in artery diameter in response to increased 
shear stress, was reduced after IR compared to baseline in patients with CAD (Figure 15). 
Administration of nor-NOHA completely prevented the development of IR-induced reduction 
in FMD (Figure 15). Importantly, FMD in the CAD group after IR was significantly greater 
following administration of nor-NOHA than following administration of saline (Figure 15). 
Baseline FMD was impaired in the CAD+diabetes group compared to the CAD group (8.3±2.0% 
vs. 12.7±5.2%, P<0.05). FMD did not significantly decrease in response to IR in patients with 
CAD+diabetes during NaCl administration. However, arginase inhibition improved FMD 
following IR compared to baseline FMD in the CAD+diabetes group (Figure 15).  
When all patients (CAD and CAD+diabetes) were analyzed together, FMD was reduced 
following IR and saline administration (10.5±4.4% baseline vs. 7.5±3.6% after IR, P<0.01) 
but FMD was not impaired after administration of nor-NOHA, instead a significant 
improvement in FMD was observed (9.2±4.3% baseline vs. 11.3±3.4% after IR, P<0.05).
Figure 15. Flow-mediated vasodilatation (FMD) at baseline and after 20 minutes ischemia and 20 
minutes reperfusion. Subjects with CAD decreased their FMD in response to ischemia-reperfusion (IR) 
during placebo administration (P<0.05). In contrast, nor-NOHA completely reversed this reduction. 
Baseline FMD was reduced among subjects with CAD+diabetes compared to CAD only (P<0.05). In 
the CAD and diabetes group FMD was not reduced in response to IR but nor-NOHA improved FMD 
above baseline despite IR. Data are presented as mean ± SD. I-R, ischemia-reperfusion; nor-NOHA, 
Nω-hydroxy-nor-L-arginine. *P<0.05, **P<0.01, ***P<0.001.
       Arginase inhibition improves endothelial dysfunction
37
EIDV induced by sublingual nitroglycerine did not differ between groups or between 
interventions. In the CAD group EIDV did not change between the two study visits (saline 
11.8±4.1% vs. nor-NOHA 14.3±5.0%). The same was true for patients with CAD+diabetes 
(13.6±6.4% following saline and 12.3±6.7% following nor-NOHA administration). The 
baseline diameter of the radial artery did not change significantly neither before vs. after IR 
nor between the experiments in any of the groups. 
Study IV
Recent experimental evidence has suggested a link between LDL and increased arginase 
activity, making hypercholesterolemia an important condition in which the functional 
significance of arginase needs to be explored.  
The groups were well matched regarding all measured parameters except for cholesterol 
levels and medications (Tables 1 and 2). LDL cholesterol increased in subjects with FH after 
4 weeks of abstaining from lipid lowering drugs compared to at inclusion (4.3±0.9 vs. 7.6±1.9 
mmol/l, P<0.001). Despite their lipid-lowering medication, the FH subjects had higher LDL 
cholesterol at inclusion than the control subjects (2.4±0.9 mmol/l, P<0.001).  
Baseline FBF did not differ between the groups nor did it change in response to nor-NOHA in 
any of the groups. Baseline EDV did not differ between the study visits or between the groups. 
Surprisingly, arginase inhibition increased EDV in all groups, including the control group. 
There were no changes in EDV in response to arginase inhibition between the first and second 
visit (low and high levels of LDL) of the FH patients. However, the improvement of EDV in 
response to nor-NOHA was greater among FH individuals than in healthy subjects (Figure 
16). EIDV did not change in response to arginase inhibition nor did it differ between visits. 
Figure 16. Improvement in endothelium-dependent vasodilatation after 120 minutes i.a. Nω-hydroxy-
nor-L-arginine (nor-NOHA) administration from baseline in healthy controls, patients with familial 
hypercholesterolemia (FH) off lipid lowering therapy and FH patients on lipid lowering therapy. All 
groups responded to the intervention but the response in the subjects with FH was significantly greater 
than that of the control subjects. No difference was observed between the visits of subjects with FH. 
Data are presented as mean ± SD. *P<0.05 compared to the response in EDV from control subjects.
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DISCUSSION
Key findings
The present studies demonstrate that arginase inhibition improves endothelial function in 
patients with CAD with and without diabetes, diabetes with microvascular dysfunction, and 
FH. The effect of arginase inhibition was evaluated in three different vascular beds in vivo. 
The main findings are that: 
•	 Arginase is expressed in left internal mammary arteries in patients with CAD and 
CAD+diabetes.
•	 Arginase inhibition improves endothelial function, via a NOS-dependent mechanism, 
among patients with CAD and especially among patients with CAD+diabetes.
•	 Arginase inhibition improves microvascular endothelial function in patients with 
diabetes and microvascular dysfunction.
•	 Amino acids reflecting relative arginase activity (in comparison to eNOS) is higher in 
patients with diabetes compared to control subjects.  
•	 Arginase inhibition improves endothelial function in an IR model in patients with 
CAD, both with and without diabetes.
•	 Arginase inhibition improves endothelial function in FH, irrespective of LDL 
cholesterol levels.
The role of arginase in basal endothelial function in patients with CAD 
and diabetes
In Study I, the role of arginase inhibition on endothelial function was determined in subjects 
with CAD with and without diabetes and in healthy subjects. Patients with CAD showed 
reduced EDV compared to healthy controls, and subjects suffering from both CAD and 
diabetes presented further reduced EDV compared to patients with CAD only. These data 
confirm that the studied patient groups had different degrees of endothelial dysfunction at 
baseline. The level of endothelial dysfunction in the CAD and diabetes group is comparable 
to another study using the same methodology (117). In addition, impaired venous endothelial 
function was demonstrated in vitro in vessels from patients with CAD with and without 
diabetes compared to control subjects. In line with our results, the CAD and diabetes group 
had further impairment in endothelial function compared to the CAD group (120). 
Arginase inhibition increased EDV in CAD patients with and without diabetes, but not in 
healthy subjects. Interestingly, the increase in EDV was significantly greater in the CAD and 
diabetes group compared to the group with CAD only, suggesting that arginase inhibition is 
more effective in subjects with CAD and diabetes. In line with our results, increased arginase 
I expression was demonstrated in coronary arteries from patients with diabetes (98). The 
same study observed reduced endothelial function in vessels from patients with and without 
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diabetes but endothelial function increased only in vessels from diabetic subjects after 
treatment with an arginase inhibitor. This provides further evidence that arginase inhibition 
can effect an improvement in endothelial function in the coronary arteries. As the positive 
effects of arginase inhibition were not observed in patients with CAD only, Beleznai and 
coworkers speculated that other mechanisms were behind the reduced endothelial function 
among patients without diabetes. However, our data obtained in vivo clearly suggest that that 
arginase is a key factor for endothelial dysfunction in CAD patients both with and without 
diabetes. This is also in line with our demonstration of expression of arginase I and II in 
endothelial cells of the left internal mammary artery from patients with CAD with as well as 
without diabetes. 
Statins have been shown to reduce arginase activity and expression in an experimental model 
of diabetes (78). Furthermore, diabetic animals have reduced endothelial function which 
is completely reversed by treatment with statins, suggesting that statins could be used to 
improve endothelial dysfunction partly by inhibiting arginase (78). We demonstrate a clear 
improvement in endothelial function in both patient groups despite ongoing statin treatment, 
suggesting that arginase inhibition is of additional value in improving endothelial function 
beyond any effect of statins alone.
     
In Study I we observed a slightly increased response in EIDV in the CAD and diabetes group 
after arginase inhibition, indicating a possibility to improve the NO-mediated signaling in 
these individuals. The mechanism behind this observation is unclear but may be the increased 
degree of oxidative stress in subjects with diabetes (121). By inhibiting arginase, uncoupling 
of eNOS might be reduced which results in less ROS (107) to react with NO from the NO 
donor. This may possibly improve NO-signaling. 
 
The effect of arginase inhibition in the microcirculation in patients with 
diabetes
Based on the clear improvement in endothelial function among subjects with diabetes 
described in Study I, we hypothesized that arginase could be an important regulator 
of endothelial function in the microvasculature. Hence, Study II sheds light on whether 
inhibition of arginase improves endothelial function in the microvasculature in subjects 
suffering from diabetes and microangiopathy. 
Study II demonstrates a significant difference in basal microvascular endothelial function 
between the diabetes group and the control subjects. This provides evidence that the studied 
population actually has endothelial dysfunction that can be detected with the method of 
measurement used. This finding is to be expected since endothelial dysfunction is thought to 
be a key mechanism behind microangiopathy in diabetes (122, 123). 
Arginase inhibition increased microvascular endothelium-dependent dilatation among 
subjects with diabetes but not in control subjects, similarly to Study I. Importantly, after 
arginase inhibition there was no significant difference in endothelial function between the 
groups, suggesting that arginase inhibition improves microvascular endothelial dysfunction 
to the level of healthy subjects in patients with diabetes. This effect was observed despite 
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the fact that the majority of patients were treated with stains and angiotensin converting 
enzyme inhibitors. Angiotensin converting enzyme inhibitors have been demonstrated to 
improve endothelial function in larger arteries and the coronary circulation (124), although, it 
seems that the effects of angiotensin converting enzyme inhibitors on endothelial function in 
resistance vessel and microcirculation are less clear (125). However, statins have been shown to 
improve microvascular dysfunction (126). Despite standard treatment, we observed impaired 
microvascular endothelial function among patients with diabetes and microangiopathy 
that could be reversed by arginase inhibition. This suggests that arginase inhibition further 
contribute to increasing endothelial function. In addition, 10 out of 12 patients with diabetes 
received at least one daily dose of insulin. Kashyap and colleagues present evidence that 
NOS activity was decreased 4-fold and that arginase activity in plasma was increased by 50% 
in a group of patients with diabetes compared to non-diabetic subjects (81). Furthermore, 
after insulin stimulation the level of arginase activity in plasma dropped in the diabetic 
subjects (81), suggesting a possible underestimation of the impact of arginase in these 
patients. In contrast to this finding we still observe additional improvement in microvascular 
endothelial function when inhibiting arginase in patients with diabetes. Five earlier studies 
have evaluated microvascular response to arginase inhibition in humans, although never in 
patients with diabetes (110, 111, 127-129). The results have been consistent, showing that 
arginase inhibition improves microvascular perfusion and endothelial function in examined 
patients. These findings further strengthen the idea that arginase is an important mediator 
of microvascular dysfunction. We provide evidence that inhibition of arginase improves 
microvascular endothelial dysfunction in patients with diabetes and microangiopathy. 
Analysis of arginase activity in vivo
An additional observation of Study II was the analysis of amino acids associated with NOS 
and arginase metabolism. We show increase levels of ornithine (the product of arginase) in 
subjects with diabetes compared to control subjects. In addition, the relative activity between 
arginase and NOS was quantified by determination of the end-product of each enzyme as a 
ratio of each other, i.e the ornithine/citrulline-ratio. Subjects with diabetes had a significantly 
higher ornithine/citrulline-ratio, which indicates that these subjects have a higher arginase 
activity in relation to NOS activity compared to the control subjects. Experimental models 
support our finding. Arginase inhibition was evaluated in an infarct model where animals 
were either given saline or nor-NOHA. Plasma samples showed a clear increase in citrulline, 
i.e. the end-product of NOS together with a decrease in ornithine after administration of 
nor-NOHA compared to animals which received saline (66). The change of the amino acid 
ratios, citrulline/ornithine and citrulline/L-arginine, were increased in animals with arginase 
blockade, suggesting a relative shift towards increased NOS activity. As we only analyzed the 
plasma amino acid levels at baseline and not after intervention, we do not know if the amino 
acid levels change after intervention in Study II. We show that the relative activity of arginase 
is increased in subjects with diabetes at baseline and that they improve their microvascular 
endothelial function after arginase blockade. Interestingly, there was no change in L-arginine 
levels between subjects with and without diabetes. It is known that arginase metabolizes 
L-arginine, thereby competing with NOS for the same substrate. One suggested mechanism 
of reduced bioavailability of NO is the lack of substrate for NOS, by which arginase may play 
an important role. It may therefore be unexpected that we did not observed any difference in 
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L-arginine levels between patients with diabetes and healthy subjects. However, the samples 
are drawn from plasma suggesting the circulatory levels of L-arginine is satisfactory but this 
might not mirror the milieu in the cells. Also, L-arginine is compartmentalized in different 
subcellular pools that have poor redistribution (130). Thus, L-arginine availability may be 
limited at the subcellular compartments of importance for NO production. No additional 
effect have been seen in microvascular reactivity administering both arginase inhibitor 
and L-arginine in subjects with hypertension, L-arginine supplementation alone showed 
no change in microvascular reactivity (110). Further supporting the notion that arginase is 
of importance for endothelial function in subjects with diabetes is the observation by our 
lab that subjects with diabetes and macrovascular complications have increased levels of 
ornithine/citrulline, ornithine/L-arginine, and proline/citrulline ratios (77, 131). These ratios 
inversely correlate with EDV and EIDV measured with venous occlusion plethysmography 
in the forearm, suggesting that arginase is involved in the regulation of vascular reactivity.
There are currently no isoform-specific arginase inhibitors available. Therefore, it is difficult to 
determine which of the two different isoforms of arginase is of pathophysiological importance 
in diabetes. Romero and coworkers investigated the role of arginase in diabetic mice in which 
the gene for arginase II was deleted together with one allele of the arginase I gene. Wild 
type diabetic mice had reduced endothelial function, increased coronary fibrosis, vascular 
stiffness, and ROS production together with increased arginase activity and expression of 
arginase I (95). Heterozygote arginase I knockout mice had lower arginase activity and 
arginase I expression, reduced coronary fibrosis, vascular stiffness, ROS-production, and 
increased endothelial function (95). The response in homozygote arginase II knockout mice 
was similar to that observed in wild type diabetic mice. Based on these observations it was 
suggested that arginase I is of major pathophysiological importance in diabetes. In contrast, a 
knockout model of arginase II has been described to enhance relaxation in corpora cavernosa, 
which is largely dependent on NO. Today there is no consensus of which isoform that is the 
most important for the regulation of endothelial function.
    
Reperfusion injury
In Study III, the acute role of arginase inhibition on endothelial function after 20 minutes 
of ischemia and 20 minutes of reperfusion was investigated using FMD. IR markedly 
reduced endothelial function in patients with CAD during administration of NaCl. In 
contrast, arginase inhibition completely prevented the IR-induced reduction of FMD. These 
observations are supported by the findings in experimental studies. Jung and co-workers 
demonstrated a reduction of infarct size by 50% after iv administration of nor-NOHA in 
an experimental IR rat model of myocardial IR (66, 112). In contrast, iv administration of 
nor-NOHA did not decrease infarct size in pigs subjected to 40 minutes of ischemia and 
4 hours of reperfusion. However, local intra-coronary infusion of nor-NOHA (2 mg/min 
for 15 min) resulted in significantly decreased infarct size, similar to the effect observed in 
rats (132). In our experiment, local nor-NOHA infusion (0.1 mg/min for 20 min) improved 
endothelial function in CAD patients. These observations suggest that if a clinical trial was to 
take place, the administration of an arginase inhibition should be administered locally i.e. by 
intra-coronary infusion during the percutaneous coronary intervention and preferably starting 
before opening of the occluded vessel. The latter is based on the protocols of pre-clinical 
studies examining cardioprotection and our protocol in Study III in which administration of 
nor-NOHA was initiated before the onset of reperfusion. 
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It is of importance to evaluate interventions against IR injury in patients with co-morbidities 
such as diabetes (113) since the efficacy of protective regimens have been demonstrated to be 
affected by co-morbidities (133) and since patients with diabetes have poorer outcome after 
myocardial infarction (60). Surprisingly, in our observations, subjects with diabetes did not 
decrease in FMD in response to IR. The reason for this is unclear. However, in the diabetes 
group, FMD was improved to levels above baseline in response to arginase inhibition despite 
the period of IR. This is of great importance as it seems to be more difficult to successfully 
treat IR injury in animals with diabetes (134). One explanation of our findings of improved 
FMD after arginase inhibition, could be that the baseline endothelial function of diabetic 
patients is poor and that arginase inhibition improves baseline endothelial function in line 
with the results from Study I. However, in Study I it took 120 min before a significant 
difference in endothelial function could be seen which suggest that the improvement by nor-
NOHA in Study III is of acute nature and therefore related to the IR injury rather than that 
the baseline endothelial function is improved. Collectively, the data suggest that arginase 
inhibition improve FMD after IR in patients with CAD with and without diabetes.  
In the clinical setting, arginase I has been shown to be upregulated in healthy subjects after 
global hypoxia (129). Furthermore, the same study observed that subjects resuscitated cardiac 
arrest had higher plasma arginase I than healthy control subjects. This is further supported 
by the observations that arginase activity was significantly increased in the myocardium 
following IR in rats subjected to myocardial IR (69). The difference was present 20 min 
and 8 days after reperfusion. Furthermore, arginase inhibition decreased arginase activity 
in ischemic myocardium compared to vehicle, both after 2 h and 8 days of reperfusion (69). 
The same study also provides evidence for decreased infarct size after arginase inhibition 
both in the acute setting and after eight days, suggesting a long-term effect despite the acute 
administration. The clear beneficial effect of single administration of an arginase inhibitor 
in IR injury in experimental animals and in patients with CAD demonstrated in Study III 
should encourage the design and initiation of a clinical trial evaluating the beneficial effect of 
arginase inhibition to reduce infarct size in patients with ST-elevation myocardial infarction. 
Challenges in translating therapies of cardioprotection to the clinic
A great number of cardioprotective therapies have been proven to reduce infarct size in 
experimental models, although the evidence showing clinical benefit in patients is scarce 
(135). The reason for this is unclear and several possible mechanisms might be involved. 
One important factor may be the confounding effect of co-morbidities. For example, the 
cardioprotective effect of remote ischemic conditioning is attenuated or absent in diabetes 
(133, 136). It is therefore of importance to investigate therapeutic strategies in patients or 
animal models with relevant co-morbidities. It is if interest that arginase inhibition improved 
endothelial function following IR in patients with CAD and diabetes in Study III. Another 
factor that may influence the therapeutic effect of protection against IR injury is other 
medication that the patients are given. Our observations provide evidence that arginase 
inhibition improves endothelial function beyond that induced by other therapies given such 
as ACE inhibitors and statins. The timing and route of intervention may be of importance. In 
our study, the arginase was given by i.a. infusion starting before the onset of reperfusion. It 
is possible that insufficient local concentration of the drug is achieved if given systemically. 
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Collectively, data obtained from the present study suggest that arginase inhibition may 
represent an attractive therapeutic strategy to protect against IR injury in the presence of co-
morbidities and in addition to other cardiovascular medications.  
Arginase inhibition, involvement of red blood cells in IR
We have observed improved endothelial function in response to the administration of 
arginase inhibitor after IR. In experimental studies, decreased infarct size has been reported 
repeatedly in animals treated with arginase inhibition compared to control animals (66, 
69, 132). However, the cellular source of the targeted arginase in this setting is unclear. 
Hitherto, functional arginase was thought to be expressed mostly by endothelial cells, where 
the majority of NO production takes place. However, red blood cells (RBCs) express vast 
amounts of arginase I, and recent data suggest that RBCs may be of great importance in 
myocardial IR. Yang and coworkers demonstrated a protective role of arginase inhibition 
in an isolated rat heart subjected to global ischemia and reperfusion (137). Interestingly, 
this protection was seen only in the presence of RBCs. Furthermore, the protective effect 
of arginase inhibition was completely dependent on RBC eNOS. These findings suggest a 
new mechanism for the communication between the RBCs and endothelium/myocardium, 
whereby RBC arginase regulates eNOS to mediate the protective effect mediated by 
arginase inhibition. The functional significance of RBCs for heart function in diabetes was 
also recently demonstrated. RBCs from diabetic mice given to wildtype hearts resulted in 
reduced recovery after IR compared to RBCs from wildtype mice (138). This reduction in 
heart recovery in diabetic mice could be counteracted by administration of NOS or arginase 
inhibitors. Together these observations suggest an important role of arginase in RBCs for the 
action of arginase inhibition in cardioprotection.
The effect of arginase inhibition on endothelial function in patients with FH
LDL is crucial for the development of atherosclerosis and has been linked to up-regulation 
of arginase. It is therefore of great interest to evaluate endothelial function and the role of 
arginase inhibition in patients with high levels of LDL. Hence, we included patients with FH 
to evaluate the effect of local arginase inhibition on endothelial function in vivo. 
Patients with FH did not have reduced EDV at baseline compared to healthy controls. 
The lipid-lowering treatment was discontinued for 4 weeks which resulted in a prominent 
increase in LDL levels among patients with FH from 4.3±0.9 to 7.6±1.9 mmol/l (P<0.001). 
Basal EDV was not impaired despite the significance increase in LDL levels in patients with 
FH. This is in contrast to reduced EDV described among patients with hypercholesterolemia 
already after 2 weeks without lipid-lowering drugs (58). 
Patients with FH had a significantly greater improvement in EDV after arginase inhibition 
compared to control subjects, regardless if the subjects with FH received lipid-lowering drugs 
or not. Holowatz and co-workers evaluated cutaneous dilatation in hypercholesterolemic 
subjects before and after atorvastatin treatment (127). During hypercholesterolemic 
conditions cutaneous vasodilatation was reduced. They further showed an improvement after 
cutaneous administration of an arginase inhibitor by microdialysis. The same study showed 
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increased arginase activity in skin biopsies collected from hypercholesterolemic subjects, 
compared to healthy controls but also compared to skin biopsies from the same patients 
after 3 months of atorvastatin treatment. Collectively these data provide supporting evidence 
that arginase is of importance for regulation of endothelial function in hypercholesterolemic 
subjects. In Study IV, arginase inhibition improved EDV both in FH with and without lipid-
lowering drugs but also among control subjects. This was a surprising finding because in 
Study I we did not observe an increase in EDV in response to arginase inhibition among 
healthy subjects. The interpretation of this finding is complex. On the other hand, all groups 
in Study IV improved in EDV but the improvement in the FH group in response to arginase 
inhibition was greater compared to healthy individuals, regardless whether they received 
lipid-lowering drugs or not. This suggests that arginase inhibition is of additional benefit in 
improving EDV compared to lipid-lowering drugs alone. 
Interestingly, several studies have described a clear link between LDL, increased arginase 
activity and reduced NO bioavailability (89, 91, 108, 139) and have examined the mechanisms 
behind it. Of great interest is that arginase inhibition improves endothelial function measured 
in vitro with vessels taken from atherogenic mice but also from wildtype mice on high fat diet 
(91). Furthermore, long-term treatment with arginase inhibition decreased the frequency and 
thickness of the plaque in atherogenic mice (91). In experimental models of atherosclerosis 
and hypercholesterolemia, arginase II has been suggested to be a key regulator of ROS 
production, NO production, and endothelial function (91, 108). New post-translational 
mechanistic insights have been demonstrated by Ryoo et al. (89), and Pandley et al. (139), 
who showed that arginase II is translocated to the cytoplasm from the mitochondrion in 
response to oxLDL. The signaling of oxLDL is mediated by LOX-1 and ROCK activation 
downstream of the receptor (139). Moreover, statins have been shown to improve endothelial 
function, reduce arginase activity, and block LOX-1-dependent ROCK signaling (78, 139, 
140). These mechanisms are of importance for the understanding of arginase activation in 
hypercholesterolemic subjects. Additionally, glucose and oxLDL have been shown to increase 
arginase activity by activating Rho (139), suggesting a common pathway for activation of 
arginase. The insights gained by describing the molecular processes behind up-regulation of 
arginase are of importance for the understanding of the pathophysiology of arginase and the 
development of new possible therapies modulating arginase. 
Strategies to improve NO bioavailability
The beneficial effect of arginase inhibition on the vascular bed seems to be mediated by 
increased NO production as the improvement in endothelial function was blocked by 
administering a NOS-inhibitor as demonstrated in Study I. If arginase inhibition works 
through NOS and increased bioavailability of NO, can’t we just administer NO to exert a 
similar effect? This has been investigated previously, although with negative results. Chronic 
treatment with organic nitrates have been show to induce nitrate tolerance and endothelial 
dysfunction (141). A similar finding was seen in patients with acute lung injury where the 
positive response to inhaled NO disappeared already after a few days of treatment (142). 
Two phase II trials have evaluated intra-venous and intra-coronary nitrite administration in 
patients with acute myocardial infarction (143, 144). None of them were able to demonstrate 
a reduction in infarct size. Although Jones et al. demonstrated reduced adverse events after 
1 year in the nitrate group (143). There are other approaches that have been used to try to 
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increase NO levels. One is administration of the substrate of NOS, L-arginine. The idea that 
administration of L-arginine would be able to increase NO production  despite the fact that 
the concentration in cells is 0.1-2 mM, in the context of the Km of NOS which is 3-6 µM 
(145), is referred to as the L-arginine paradox (146). In addition, the Km for arginase (5 
mM) is lower than that of NOS. However, the maximum activity for arginase far exceeds 
that of NOS about 1000 fold (147). In the experimental setting L-arginine administration 
has shown promising results. In contrast, administration of L-arginine has not demonstrated 
beneficial effects in patients with myocardial infarction (148). Another clinical study 
showed a significant reduction in FMD in patients with leg claudication after 6 month of 
oral L-arginine supplementation compared to placebo (149). L-arginine supplementation 
increased plasma levels of L-arginine, but citrulline and NO levels were not affected. Wilson 
et al speculated that arginase up-regulation might be of importance in causing this lack 
of effect. However, the high levels of L-arginine would imply that the L-arginine was not 
extensively metabolized, at least not reflected in plasma samples. Of further importance is the 
observation that L-arginine treatment does not seem to improve endothelial function in vitro 
beyond that induced by arginase inhibition alone (98, 110). Another therapy tried in the clinic 
is administration of BH4, a co-factor for NOS, but this also demonstrated a limited effect in 
patients with CAD (150). 
Why would arginase inhibition be more beneficial than the therapies improving NO 
bioavailability described above? Oxidative stress has been shown to reduce co-factors, induce 
uncoupling of NOS, and react with NO. During a state of increased inflammation, such as in 
diabetes or atherosclerosis, delivery of exogenous NO will probably react with ROS, rapidly 
forming peroxynitrite. One problem with administration of substrate and co-substrate could 
be that they don’t reach the NOS enzyme in the endothelial cells. L-arginine for example 
is divided among many subcellular compartments, with poor interchangeability (130). 
Arginase inhibition may improve synthesis and reduce elimination of NO through shunting 
of L-arginine to NOS and by reducing NOS uncoupling. The shunting of L-arginine, though 
arginase inhibition, might normalize the production of NO. Reduced NOS uncoupling yields 
decreased ROS production and oxidative stress. Arginase inhibition may exert synergistic 
effects to preserve the bioavailability of NO. 
 
Improved endothelial function, does it matter?
We have demonstrated improvement in endothelial function in subjects with CAD, diabetes, 
and FH in response to arginase inhibition. However, one question remains unanswered. Does 
improvement in endothelial function actually matter? Evidence suggests that endothelial 
dysfunction is an independent risk factor for cardiovascular disease (10, 151). Similar results 
are observed in the Swedish population (152). These data suggest that the study population 
has an increased risk for cardiovascular events. Based on these observations therefore 
endothelial dysfunction was used as a surrogate clinical endpoint. However, it has not been 
demonstrated if improvement in endothelial function per se decreases cardiovascular events 
in any randomized controlled trials, mostly due to a of lack of agents specifically acting on 
endothelial function. Antihypertensive therapy (153) and statins improve endothelial function 
and reduced mortality from cardiovascular disease (140, 154). Collectively, much evidence 
suggests a connection between endothelial dysfunction and increased risk for cardiovascular 
disease but causality has not been evaluated in any randomized clinical trial. 
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Limitations 
There are certain limitations associated with these studies. The size of the study groups is small, 
increasing the risk of type 1 and type 2 errors. However, based on pilot studies, we estimated 
the number of subjects needed to detect a difference in the predetermined primary endpoint, 
and met the estimated population size in all our studies. Furthermore, the smaller sample 
size makes it possible for mechanistic proof-of-concept studies. Endothelial dysfunction is a 
surrogate endpoint and the magnitude of difference in this endpoint is difficult to estimate. 
As discussed above, endothelial dysfunction is an independent predictor of the risk factors 
for cardiovascular events and co-varies with an improvement of these other risk factors such 
as LDL, suggesting it is a clinically relevant outcome to measure. In this thesis endothelial 
function has been evaluated in the arteries of the forearm, and it might be argued that 
atherosclerotic disease or plaque commonly causes symptoms in the legs, heart, and/or brain. 
However, studies evaluating endothelial dysfunction in both the heart and the arm have shown 
a clear correlation of endothelial function measured between the two vascular beds (155). 
Furthermore, atherosclerosis is a systemic disease, even if people rarely have flow-limiting 
plaque formation in the arm, the disease is nevertheless still present. A drawback is that there is 
no clear evidence fin support of which isoform of arginase is responsible for the improvement 
in endothelial function, as the substance nor-NOHA is an unselective arginase blocker and no 
selective arginase inhibitor is currently available. These studies are limited to local and short-
term administration of the arginase inhibitor in the brachial artery whereas oral administration is 
needed to evaluate its efficacy as a long-term treatment. Since arginase is of great importance in 
the liver, there is the possibility that inhibiting liver arginase may risk inducing hyper ammonia 
if high doses of arginase inhibition are administered. However, the levels of arginase in the 
liver far exceed those found in the vasculature, hence, the small doses of arginase inhibition 
effecting the vasculature would probably have a minimal effect in the liver. A few studies have 
evaluated the safety of long-term arginase inhibition and so far no adverse events have been 
reported (109, 156). Although the methods employed in Studies I-IV are user-dependent, by 
using qualified, trained technicians variation could be kept to a minimum. 
Future perspective
Arginase as an enzyme has been known for long but the research field of arginase as a 
therapeutic target is in its infancy. Much evidence suggests a central role of arginase for 
regulation of endothelial function, yet many questions remain unanswered. Which isoform of 
arginase is of greatest pathophysiologic importance? What role does arginase have in RBCs 
and how does it affect homeostasis? Will arginase inhibition improve clinical outcome for 
patients with increased cardiovascular risk? These are a few of the areas where knowledge 
is lacking, and in great need of further research. Of course, additional studies need to be 
performed to confirm the results of the work of this thesis. In addition, larger and long-term 
studies with clinical end-points need to be performed before we can establish the true benefit 
of arginase inhibitors. 
 
In our laboratory, new studies investigating the role of arginase for endothelial function at 
different levels of glycemic control in patients with diabetes are currently ongoing. In addition, 
the role of arginase in RBCs and the effect on endothelial function is being investigated. 
Furthermore, arginase has been suggested as playing a role in endothelial dysfunction in 
obese subjects (157), which is of great interest as there is an epidemic of obesity in today’s 
society (158). 
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Arginase inhibitors are starting to be developed for clinical use. For example, in the field of 
cancer research arginase inhibition has been suggested to decrease tumors and is currently 
under clinical investigation. One study is recruiting subjects with advanced cancer diagnosis 
to investigate the safety and tolerability of oral administration of the arginase inhibitor CB-
1158 (clinicaltrials.gov, accessed; 2017-03-13). This is of great interest as dose and toxicity 
are pressing concerns for all newly developed drugs. However, the dose yielding effect on 
tumors might be greatly different from the dose to be used in treatment of cardiovascular 
disease. Several companies have variants of arginase inhibitors but few have the focus 
to develop them with the indication of cardiovascular disease. Communications between 
the academia and industry have resulted in possible projects which might speed up the 
development of arginase inhibitors for cardiovascular disease. 
Diseases caused by atherosclerosis are still the most frequent cause of death and disability 
worldwide. As endothelial dysfunction is a key mediator of atherosclerosis, perhaps the 
onset of clinical manifestation may be postponed or even hindered by improving impaired 
endothelial function. As patients with diabetes have reduced endothelial function and do 
not show significant reduction of cardiovascular mortality from classical glucose-lowering 
drugs, new therapies are greatly needed for this patient group, arginase inhibition could be 
one potential treatment. This is supported by the data presented in this thesis as arginase 
inhibition improves endothelial function in three different vascular beds in subjects with 
diabetes (Figure 17). Furthermore, if we could translate the result of cardioprotection, 
observed in experimental studies, into the clinical setting, then patients with myocardial 
infarction might have a better outcome. 
Figure 17. Evaluation of endothelial function in subjects with diabetes in three different vascular beds. In 
Study I, endothelial-dependent vasodilatation (EDV) was measured in resistance vessels with venous 
occlusion plethysmography before and after 120 minutes administration of nor-NOHA, Nω-hydroxy-
nor-L-arginine (nor-NOHA). Nor-NOHA improved in subjects with CAD+diabetes (n=16). In Study II, 
microvascular endothelial function was measured with laser Doppler flowmetry before and after 120 minutes 
administration of nor-NOHA. Microvascular endothelial function was improved in subjects with diabetes and 
microangiopathy following administration of nor-NOHA (n=12). In Study III, flow-mediated vasodilatation 
(FMD) was used to evaluate conduit artery endothelial function before and after a period of 20 minutes 
ischemia and 20 minutes reperfusion. Nor-NOHA improved FMD compared to administration of NaCl in 
patients with CAD and diabetes (n=12). Collectively, administration of nor-NOHA improved endothelial 
function regardless of type of vascular bed. Data are presented as mean ± SD. Ach, acetylcholine; FBF, 
forearm blood flow; FMD, flow-mediated vasodilatation; IR, ischemia-reperfusion; mA, milliampere. 
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CONCLUSIONS
I. Arginase inhibition improves basal endothelial function in patients with CAD 
without and with type 2 diabetes through a NOS-dependent mechanism. The positive 
effect of arginase inhibition was especially pronounced among patients with type 2 
diabetes.
II. Arginase inhibition improves microvascular endothelial function in patients with 
type 2 diabetes and microvascular dysfunction. 
III. Arginase inhibition improves IR-mediated endothelial dysfunction in patients with 
CAD. 
IV. Arginase inhibition improves endothelial function in patients with familial 
hypercholesterolemia, irrespective of cholesterol levels. 
Collectively, these results demonstrate the importance of arginase for endothelial function in 
patients with CAD, type 2 diabetes, and hypercholesterolemia. Arginase is thus a promising 
therapeutic target in the future treatment of endothelial dysfunction in patients with CAD, 
type 2 diabetes, or hypercholesterolemia. 
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